BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

Search

UCB SA

Atidarymo kaina

SektoriusSveikatos priežiūra

149.5 1.77

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

145.2

Max

149.5

Pagrindiniai rodikliai

By Trading Economics

Pajamos

208M

Pardavimai

2.8B

P/E

Sektoriaus vid.

24.872

57.333

Pelnas, tenkantis vienai akcijai

2.09

Dividendų pajamingumas

1.02

Pelno marža

7.453

Darbuotojai

9,052

EBITDA

644M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+19.23% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.02%

2.63%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-9.8B

26B

Ankstesnė atidarymo kaina

147.73

Ankstesnė uždarymo kaina

149.5

UCB SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-24 23:54; UTC

Karštos akcijos

Stocks to Watch: Alphabet, Intel, AppFolio

2025-04-24 23:51; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

2025-04-24 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-04-24 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

2025-04-24 23:37; UTC

Svarbiausios naujienos

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

2025-04-24 23:36; UTC

Svarbiausios naujienos

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

2025-04-24 23:13; UTC

Svarbiausios naujienos
Uždarbis

Google's Earnings Power Holds Up in Global Turbulence -- Update

2025-04-24 23:09; UTC

Svarbiausios naujienos

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

2025-04-24 23:02; UTC

Įsigijimai, susijungimai, perėmimai

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

2025-04-24 23:02; UTC

Įsigijimai, susijungimai, perėmimai

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

2025-04-24 22:51; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

2025-04-24 22:48; UTC

Svarbiausios naujienos

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

2025-04-24 22:47; UTC

Rinkos pokalbiai

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

2025-04-24 22:38; UTC

Rinkos pokalbiai
Uždarbis

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

2025-04-24 22:24; UTC

Uždarbis

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

2025-04-24 22:24; UTC

Uždarbis

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

2025-04-24 22:24; UTC

Rinkos pokalbiai
Uždarbis

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

2025-04-24 22:23; UTC

Uždarbis

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

2025-04-24 22:11; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-04-24 22:11; UTC

Rinkos pokalbiai
Uždarbis

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

2025-04-24 22:09; UTC

Svarbiausios naujienos
Uždarbis

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

2025-04-24 22:00; UTC

Rinkos pokalbiai
Uždarbis

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

2025-04-24 21:39; UTC

Svarbiausios naujienos

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

2025-04-24 21:24; UTC

Svarbiausios naujienos
Uždarbis

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

2025-04-24 21:24; UTC

Svarbiausios naujienos
Uždarbis

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

2025-04-24 21:23; UTC

Svarbiausios naujienos
Uždarbis

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

2025-04-24 21:04; UTC

Uždarbis

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

2025-04-24 21:03; UTC

Uždarbis

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

2025-04-24 21:03; UTC

Uždarbis

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

2025-04-24 21:02; UTC

Uždarbis

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Akcijų palyginimas

Kainos pokytis

UCB SA Prognozė

Kainos tikslas

By TipRanks

19.23% į viršų

12 mėnesių prognozė

Vidutinis 94.86 EUR  19.23%

Aukščiausias 125 EUR

Žemiausias 74 EUR

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines UCB SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

7 ratings

4

Pirkti

1

Laikyti

2

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.